We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verseon (DI) | LSE:VSN | London | Ordinary Share | COM USD0.001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 74.00 | 70.00 | 78.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVSN
RNS Number : 6720R
Verseon Corporation
04 March 2019
March 4, 2019
Verseon Corporation
("Verseon" or the "Company")
Additional Listing & Total Voting Rights
Fremont, Calif.-Verseon, a technology-based pharmaceutical company, announces that application has been made for 4,375 new shares of common stock ("Common Shares") of par value $0.001 each to be admitted to trading on AIM pursuant to regularly scheduled vesting of restricted stock units (the "Issuance").
The 4,375 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on March 7, 2019 ("Admission").
Total Voting Rights
Following Admission, the issued share capital of the Company will consist of 151,699,413 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 151,656,496. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Other Information
Further to the announcement of November 6, 2018, Verseon also confirms the completion of normal and customary regulatory diligence on Sangtae Kim, a non-executive director of the Company. In relation to Mr. Kim's appointment, the following information is disclosed pursuant to Schedule 2, paragraph (g) of the AIM Rules for Companies:
Full Name: Sangtae Kim Age: 60 -------------------------------------- Current Directorships Purdue University / Partnership: -------------------------------------- Previous Directorships Prowd Sciences Inc. / The Morgridge Institute for Research Partnership in the Inc. past 5 years: -------------------------------------- Shareholding in the Nil Company: --------------------------------------
- Ends -
For further information, please contact:
Verseon Corporation www.verseon.com Sebastian Wykeham / Tina Schlafly +1 (510) 225 9000 Arden Partners (NOMAD and Joint Broker) Ruari McGirr / Ciaran Walsh / Alex +44 (0) 20 7614 Penney 5900 Cantor Fitzgerald Europe (Joint Broker) +44 (0) 20 7894 Phil Davies 7000
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers) +44 (0) 20 7466 Henry Harrison-Topham / Jamie Hooper 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts +44 (0) 1737 821 Simon Vane Percy 890
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ALSJJMFTMBMMBBL
(END) Dow Jones Newswires
March 04, 2019 02:01 ET (07:01 GMT)
1 Year Verseon Chart |
1 Month Verseon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions